Navigation Links
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Date:5/21/2008

.

Worsening congestive heart failure (CHF) has been observed with TNF-blocking agents, including HUMIRA, and new onset CHF has been reported with TNF-blocking agents. Treatment with HUMIRA may result in the formation of autoantibodies and rarely, in development of a lupus-like syndrome.

In the placebo-controlled clinical studies of adult patients with rheumatoid arthritis, the most frequent adverse reactions vs. placebo were injection site reactions (20 percent vs. 14 percent), upper respiratory infection (17 percent vs. 13 percent), injection site pain (12 percent vs. 12 percent), headache (12 percent vs. 8 percent), rash (12 percent vs. 6 percent) and sinusitis (11 percent vs. 9 percent). Discontinuations due to adverse events were 7 percent for HUMIRA and 4 percent for placebo.

In HUMIRA clinical trials for ankylosing spondylitis, psoriatic arthritis, Crohn's disease and plaque psoriasis, the safety profile for adult patients treated with HUMIRA was similar to the safety profile seen in adult patients with rheumatoid arthritis. In the placebo-controlled clinical trials in plaque psoriasis, the incidence of arthralgia was 3 percent in HUMIRA-treated patients versus 1 percent in controls.

In general, adverse reactions in pediatric patients were similar in frequency and type to those seen in adult patients. Severe adverse reactions reported in the clinical trial of juvenile idiopathic arthritis (JIA) included neutropenia, streptococcal pharyngitis, increased aminotransferases, herpes zoster, myositis, metrorrhagia and appendicitis. Serious infections were observed in 4 percent of patients within approximately 2 years of initiation of treatment with HUMIRA and included cases of herpes simplex, pneumonia, urinary tract infection, pharyngitis, and herpes zoster. Safety of HUMIRA in pediatric patients for uses other than JIA has not been established.

As with any treatment program, the benefits and risks of HUMIRA should be carefully co
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
4. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
5. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Hurel Corporation ("Hurel"), a ... cell-based assay platforms, today announced the appointment of ... the Company,s Board of Directors. Dr. MacDonald is the ... Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical development ... Merck & Co. in 2009. Over a ...
(Date:5/21/2013)... BioElectronics Corp. (PINKSHEETS: BIEL), the maker ... that CEO, Andrew J. Whelan ... Advisory Committee, Orthopedic and Rehabilitation Panel compelling arguments ... counter sales. "It,s been 37 years ... schema," Whelan said.  "While the old classification of ...
(Date:5/21/2013)...   Accuray Incorporated (Nasdaq: ... results involving hundreds of prostate cancer patients treated ... widely used form of prostate stereotactic body radiation ... a median of 5 years, and many to ... of patients with low-risk and 90.7% of patients ...
Breaking Medicine Technology:Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3
(Date:5/21/2013)... LEAWOOD, Kan. Primary care practice transformation on ... health care reform efforts aimed at achieving better ... Amid emerging evidence that transformation toward the patient-centered ... today,s health care environment, the U.S. Department of ... and Quality funded 14 studies to learn more ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Mecklenburg EMS ... will hold a free Community Wellness Fair to educate ... The fair will be held on Wednesday, May 22, 2013 ... City YMCA (8100 Old Mallard Creek Road, Charlotte, NC ... Heart Association and the Mecklenburg County Department of ...
(Date:5/21/2013)... Orsiro stent, which is a novel stent platform ... to the Xience Prime everolimus-eluting stent for the ... at nine months in the results of an ... The BIOFLOW-II substudy used intravascular ultrasound (IVUS) and ... hyperplasia and stent apposition at nine months after ...
(Date:5/21/2013)... Boca Raton, Fla. (PRWEB) May 21, 2013 ... TV program distributed on cable networks and cable channels ... of new episodes on its YouTube channel. The producers ... profiles of companies in the shipping industry, the manufacturing ... program highlights pioneering medical facilities and medical practitioners in ...
(Date:5/21/2013)... 21, 2013 MedMar Healing Center ... benefit Second Harvest Food Bank. Twenty-eight businesses, including MedMar Healing ... the food drive. The goal is to raise food to ... problems facing their families in recent years. , “We ... help those in need,” explains Douglas Chloupek of MedMar Healing ...
Breaking Medicine News(10 mins):Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2
... Covance Inc. (NYSE: CVD ) today announced that ... on Wednesday, March 11, 2009 at 1:30 p.m. (ET). ... www.covance.com . In order to register and download ... headquarters in Princeton, New Jersey, is one of the world,s ...
... California, San Diego School of Medicine have identified a key ... to divide and replicate themselves. The rapid generation of ... body,s antibody defense mechanism. However, when B cells grow ... multiple myeloma or, when they grow to attack the wrong ...
... Selects Desktop and Production Messaging Solutions for Significant Savings, ... ... Norcross, GA (PRWEB) March 8, ... (NasdaqCM: ESIC)(easylink.com), a global provider of comprehensive messaging services, ...
... Jacqueline Foreman is pleased to be interviewing Dr. Barry Sears ... Talk Radio on Blogtalkradio at www.blogtalkradio.com/yourmentalhealth on Tuesday, ... Listeners are encouraged to call in with their questions at ... join our live members only chat session. If you miss ...
... as family situations change, study finds , , SATURDAY, March ... spoiling grandchildren, but a new study says they might ... and behavior. , Spending time with grandma ... divorced/separated or stepfamily households, according to the report, published ...
... Church of Scientology,s Freedom Magazine article on psychiatric screening was ... , ... Los Angeles, Ca (PRWEB) March 6, 2009 ... has been recognized by the Religion Communicators Council (RCC) with the ...
Cached Medicine News:Health News:Protein helps immune cells to divide and conquer 2Health News:Email Fax Provider, EasyLink Services, Announces Prominent Bio-Pharma Signing 2Health News:Email Fax Provider, EasyLink Services, Announces Prominent Bio-Pharma Signing 3Health News:Zone Diet Creator Dr. Barry Sears to Talk About Latest Book Toxic Fat: When Good Fat Turns Bad 2Health News:Zone Diet Creator Dr. Barry Sears to Talk About Latest Book Toxic Fat: When Good Fat Turns Bad 3Health News:In Tough Times, Kids May Find Solace With Grandparents 2Health News:Scientology Magazine Earns Religion Communicators Council Award 2
... Synergy T-EP - EMG/EP monitoring systems range ... T2EP, T5EP and T10EP systems. These 2, ... in collaboration with leading practitioners, for ease ... of clinical testing. Synergy T-EP harnesses PC ...
Neuropack Sigma MEB-5500 series evoked potential measuring system is a compact, portable, all-in-one unit....
... MYOHANDY family are probably the most ... SystemPLUS line. Based on last generation ... the ISA 100x EP series with ... EP) , 4 channels (ISA 1004, ...
Sierra II power & efficiency plus. Sierra II report generator with automatic sentence generation creates the one-minute report. Complete 2/4 channel EMG/NCV/EP....
Medicine Products: